{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:58:53Z","timestamp":1776128333577,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116678","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:26:42Z","timestamp":1773361602000},"page":"116678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0671-2807","authenticated-orcid":false,"given":"C\u00e9cile","family":"Vicier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedjla","family":"Allouache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy","family":"Delva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1554","authenticated-orcid":false,"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0894","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Priou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Krakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Berdah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Baciuchka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FlechonAude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Cojean-Zelek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0893-285X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7453-1352","authenticated-orcid":false,"given":"Jean-Luc","family":"Labourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paule","family":"Chinet-Charrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-727X","authenticated-orcid":false,"given":"Eric","family":"Legouffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-L\u00e9on","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-1452","authenticated-orcid":false,"given":"Claude","family":"Linassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Deplanque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Davin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Brihoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-2637","authenticated-orcid":false,"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-0939","authenticated-orcid":false,"given":"Gw\u00e9na\u00ebl","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.116678_bib1","first-page":"348","article-title":"Who dies from prostate cancer? Prostate cancer prostatic","volume":"17","author":"Patrikidou","year":"2014","journal-title":"Dis D\u00e9C"},{"issue":"2","key":"10.1016\/j.ejca.2026.116678_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol F\u00e9vr"},{"issue":"4","key":"10.1016\/j.ejca.2026.116678_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116678_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol juin"},{"issue":"7","key":"10.1016\/j.ejca.2026.116678_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116678_bib6","article-title":"Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","author":"Fizazi","year":"2018","journal-title":"ESMO"},{"issue":"6","key":"10.1016\/j.ejca.2026.116678_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clgc.2020.03.017","article-title":"Long-term castration-related outcomes in patients with high-risk localized prostate cancer treated with androgen deprivation therapy with or without docetaxel and estramustine in the UNICANCER GETUG-12 Trial","volume":"18","author":"Dumont","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116678_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol F\u00e9vr"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116678_bib9","article-title":"Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): an ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs)","volume":"43","author":"Ravi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116678_bib10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol"},{"issue":"282","key":"10.1016\/j.ejca.2026.116678_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc juin"},{"issue":"15","key":"10.1016\/j.ejca.2026.116678_bib12","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2026.116678_bib13","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna (Austria): R Foundation for Statistical Computing; 2018."},{"key":"10.1016\/j.ejca.2026.116678_bib14","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: A platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw."},{"issue":"2","key":"10.1016\/j.ejca.2026.116678_bib15","first-page":"114","article-title":"bshazard: A flexible tool for nonparametric smoothing of the hazard function","volume":"6","author":"Rebora","year":"2014","journal-title":"R Journal"},{"key":"10.1016\/j.ejca.2026.116678_bib16","unstructured":"Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-12. Disponible sur: https:\/\/CRAN.R-project.org\/package=cmprsk."},{"issue":"1","key":"10.1016\/j.ejca.2026.116678_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4310\/SII.2019.v12.n1.a10","article-title":"Fine\u2013Gray proportional subdistribution hazards model for competing risks data under length-biased sampling","volume":"12","author":"Zhang","year":"2019","journal-title":"Stat Interface"},{"issue":"2","key":"10.1016\/j.ejca.2026.116678_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10985-014-9313-9","article-title":"Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals","volume":"21","author":"Li","year":"2015","journal-title":"Lifetime Data Anal"},{"issue":"10","key":"10.1016\/j.ejca.2026.116678_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","article-title":"Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"98","author":"Stephenson","year":"2006","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.ejca.2026.116678_bib20","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1200\/JCO.2008.18.2501","article-title":"Prostate cancer\u2013specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era","volume":"27","author":"Stephenson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116678_bib21","unstructured":"Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural History of Progression After PSA Elevation Following Radical Prostatectomy."},{"key":"10.1016\/j.ejca.2026.116678_bib22","unstructured":"Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy."},{"issue":"6","key":"10.1016\/j.ejca.2026.116678_bib23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.eururo.2014.09.019","article-title":"Nomogram predicting prostate cancer\u2013specific mortality for men with biochemical recurrence after radical prostatectomy","volume":"67","author":"Brockman","year":"2015","journal-title":"Eur Urol juin"},{"issue":"6","key":"10.1016\/j.ejca.2026.116678_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","article-title":"Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence","volume":"59","author":"Boorjian","year":"2011","journal-title":"Eur Urol juin"},{"issue":"9","key":"10.1016\/j.ejca.2026.116678_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ejca.2026.116678_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur Urol juin"},{"issue":"18","key":"10.1016\/j.ejca.2026.116678_bib27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jnci\/djg043","article-title":"Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy","volume":"95","author":"D\u2019Amico","year":"2003","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"28","key":"10.1016\/j.ejca.2026.116678_bib28","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","article-title":"Predictors of prostate cancer\u2013specific mortality after radical prostatectomy or radiation therapy","volume":"23","author":"Zhou","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2026.116678_bib29","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1158\/1078-0432.CCR-05-1668","article-title":"Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy","volume":"11","author":"Slovin","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ejca.2026.116678_bib30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:18:29Z","timestamp":1776125909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0959804926004582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116678","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116678"}}